What is ApiJect Systems?
ApiJect Systems is a public-benefit medical technology company focused on revolutionizing the delivery of injectable medications. The ApiJect Platform is designed to enable pharmaceutical and biotech firms to scale the production of prefilled injectors and efficiently manage the fill-finish process for their drug products. This innovative approach can be implemented through proprietary ApiJect-licensed Blow-Fill-Seal packaging lines or by leveraging the company's network of world-class manufacturing partners, aiming to make prefilled injections more accessible across diverse markets.
How much funding has ApiJect Systems raised?
ApiJect Systems has raised a total of $111M across 1 funding round:
Other Financing Round
$111M
Other Financing Round (2022): $111M with participation from Jefferies and Royalty Pharma
Key Investors in ApiJect Systems
Jefferies
Jefferies is a global investment banking and capital markets firm that provides a wide range of financial services, including advisory, underwriting, and corporate lending. Their involvement suggests a strategic financial backing for ApiJect Systems' growth and expansion initiatives.
Royalty Pharma
Royalty Pharma is a leading funder of innovation in the biopharmaceutical industry, specializing in acquiring biopharmaceutical royalties. Their participation indicates confidence in ApiJect Systems' technology and its potential to generate significant future revenue streams through its drug delivery platform.
What's next for ApiJect Systems?
The recent major strategic investment in ApiJect Systems signals a pivotal moment for the company, likely enabling accelerated scaling of its manufacturing capabilities and broader market penetration. This capital infusion is expected to bolster its efforts in partnering with pharmaceutical and biotech companies to bring the ApiJect Platform to a wider audience. The company's focus on scalable prefilled injectors positions it to address critical needs in drug delivery, potentially enhancing patient access and treatment adherence globally. Future growth will likely involve expanding its network of manufacturing partners and securing new licensing agreements.
See full ApiJect Systems company page
